The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)
Publications
Pleuroparenchymal fibroelastosis as a late complication of childhood cancer therapy: A case series.
Pediatric blood & cancer. 2024;71(7):e31004
Beynat-Mouterde C, Beltramo G, Lezmi G, Pernet D, Camus C, Fanton A, Foucher P, Cottin V, Bonniaud P
Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents.
The European respiratory journal. 2014;44(2):523-7